Key Points
- Allison Hoffman, Phreesia's General Counsel, sold 6,176 shares on March 23 at an average price of $11.97, for a total of $73,926.72.
- After the transaction she owns 163,485 shares (about $1.96M), representing a 3.64% decrease in her stake.
- Phreesia trades in the low teens (opened $11.24) with a market cap near $678M, a 12‑month range of $10.75–$32.76, and an analyst consensus of "Moderate Buy" with an average target of $28.94.
Phreesia, Inc. (NYSE:PHR - Get Free Report) General Counsel Allison Hoffman sold 6,176 shares of the stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $11.97, for a total transaction of $73,926.72. Following the completion of the transaction, the general counsel owned 163,485 shares of the company's stock, valued at $1,956,915.45. This trade represents a 3.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Phreesia Price Performance
Shares of NYSE:PHR opened at $11.24 on Thursday. The stock has a market cap of $677.84 million, a price-to-earnings ratio of -112.42 and a beta of 0.67. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.44 and a quick ratio of 2.44. Phreesia, Inc. has a 12 month low of $10.75 and a 12 month high of $32.76. The stock's 50 day moving average price is $12.81 and its 200 day moving average price is $18.05.
Analyst Ratings Changes
A number of research analysts recently issued reports on PHR shares. Wells Fargo & Company began coverage on Phreesia in a report on Thursday, January 8th. They set an "overweight" rating and a $30.00 target price on the stock. Robert W. Baird lowered their price objective on shares of Phreesia from $31.00 to $25.00 and set an "outperform" rating on the stock in a research note on Wednesday, December 10th. Citigroup cut their target price on shares of Phreesia from $29.00 to $25.00 and set a "buy" rating for the company in a research note on Friday, January 9th. JPMorgan Chase & Co. decreased their price target on shares of Phreesia from $29.00 to $24.00 and set an "overweight" rating on the stock in a research report on Friday, February 20th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $35.00 price objective on shares of Phreesia in a research report on Monday, December 8th. Seventeen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $28.94.
View Our Latest Stock Analysis on Phreesia
Institutional Investors Weigh In On Phreesia
Hedge funds have recently bought and sold shares of the business. Federated Hermes Inc. acquired a new stake in Phreesia during the 3rd quarter worth about $32,000. Asset Management One Co. Ltd. purchased a new stake in shares of Phreesia in the third quarter worth approximately $45,000. Van ECK Associates Corp lifted its position in shares of Phreesia by 78.7% in the fourth quarter. Van ECK Associates Corp now owns 2,502 shares of the company's stock worth $42,000 after purchasing an additional 1,102 shares in the last quarter. Rockefeller Capital Management L.P. boosted its holdings in shares of Phreesia by 354.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 2,755 shares of the company's stock worth $47,000 after purchasing an additional 2,149 shares during the period. Finally, KBC Group NV grew its position in Phreesia by 83.4% during the fourth quarter. KBC Group NV now owns 3,449 shares of the company's stock valued at $58,000 after purchasing an additional 1,568 shares in the last quarter. 92.10% of the stock is owned by hedge funds and other institutional investors.
About Phreesia
(
Get Free Report)
Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company's cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.
Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
